KBY Biotech Indexv0.0.34
Search
← Pipeline|OCT-7288

OCT-7288

Phase 2/3
By Octant Bio
Source: Trial-derived·Trials: 1
Modality
Peptide
MOA
Menini
Target
CD123
Pathway
PI3K/AKT
ALSProstate CaHemophilia A
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
~Jun 2021
→ ~Sep 2022
Phase 2
Dec 2022
→ Apr 2027
Phase 2Current
NCT03850365
1,066 pts·ALS
2022-12→2027-04·Recruiting
1,066 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-165mo awayPh1 Dose Esc· ALS
2027-04-121.0y awayPh3 Readout· ALS
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Recruit…
Catalysts
Ph1 Dose Esc
2026-08-16 · 5mo away
ALS
Ph3 Readout
2027-04-12 · 1.0y away
ALS
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03850365Phase 2/3ALSRecruiting1066SeizFreq
Competitors (10)
DrugCompanyPhaseTargetMOA
MavutenlimabJohnson & JohnsonPhase 3Cl18.2Menini
IvorelsinEli LillyApprovedJAK1Menini
NVO-2974Novo NordiskNDA/BLAPARPMenini
REG-7737RegeneronPreclinicalCD123WRNi
IvotuximabMadrigal PharmaPhase 2CD123CFTRmod
OlpafutibatinibImmunocoreApprovedSMN2Menini
ZorizumabBeamApprovedCD123AuroraAi
AdagralucimabCaribou BioNDA/BLACD123RAS(ON)i
TXG-675510x GenomicsApprovedCD123Menini
ZoricapivasertibCSL LimitedPhase 2HER2Menini